iBio Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Significant Transactions (Details)

Significant Transactions (Details)								3 Months Ended		12 Months Ended
Significant Transactions (Details)	Apr. 21, 2025 USD ($)	Jan. 29, 2025 USD ($) shares	Jan. 28, 2025 USD ($) shares	Feb. 25, 2024 USD ($)	Sep. 16, 2022 USD ($) shares	Nov. 01, 2021 USD ($) $ / shares shares	Aug. 23, 2021 USD ($) shares	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2025 USD ($)	Sep. 16, 2022	Sep. 16, 2022 lease
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accrued licensing fee payable								$ 850,000			$ 1,345,000
General and administrative expenses								$ 2,501,000	$ 2,801,000
PD-1 Asset Purchase Agreement \| Otsuka Pharmaceutical \| Intellectual Property
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of intellectual property				$ 1,000,000
Potential contingent payments related to sale of intellectual property				$ 52,500,000
The Purchase and Sale Agreement \| College Station Investors
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase price for Ground Lease Property						$ 28,750,000
Proceeds from sale of building						28,000,000
Base rent expense						$ 151,450
Interest rate on lease (percentage of facility's market value)						6.50%
The Credit Agreement \| Woodforest National Bank
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Principal amount borrowed						$ 22,375,000
The Warrant \| Bryan Capital \| iBio Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants, shares issued \| shares						2,579
Exercise price per share of warrants \| $ / shares						$ 665
Warrants issued and exercisable \| shares						579
Value of exercisable warrants						$ 217,255
Collaboration, Option and License Agreement \| RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration and license agreement, agreement term							5 years
AstralBio Exclusive License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of upfront licensing fee		$ 750,000	$ 750,000
Aggregate potential milestone payments payable in licensing agreement			$ 28,000,000
Equity ownership (ceiling)			19.90%
Number of shares issued per agreement \| shares		246,087	246,087
Activin E License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of upfront licensing fee	$ 750,000
Aggregate potential milestone payments payable in licensing agreement	$ 28,000,000
Equity ownership (ceiling)	19.90%
Stock Purchase Agreement \| RubrYc Therapeutics \| Series A-2 Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares purchased in transaction \| shares							2,864,345
Value of shares purchased in transaction							$ 7,500,000
Asset Purchase Agreement \| RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Liability for contingent consideration					$ 5,000,000
Cash advances to RubrYc to support operations					484,000
Transaction costs					208,000
Impairment of investment in RubrYc										$ 1,760,000
Impairment of current prepaid expense										288,000
Impairment of noncurrent prepaid expense										$ 864,000
Number of equipment leases assumed in asset acquisition												3	3
Financing lease liabilities assumed in acquisition					$ 814,000
Asset Purchase Agreement \| RubrYc Therapeutics \| iBio Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued per agreement \| shares					5,117
Fair value of shares issued in agreement					$ 1,000,000
Fair value of shares issued and subject to lockup period					$ 650,000